Development, production, and marketing of generic drugs, biosimilars, and innovative medicines.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: May 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Neopharmed Gentili S.P.A
B
Development, production, and commercialization of high therapeutic value pharmaceutical solutions across multiple therapeutic areas.
STADA Group
B
Manufacturing and distribution of high-quality pharmaceuticals, including consumer healthcare products, generics, and specialty medicines.
Initiatives identified among leaders
Gouvernance ESG
“STADA Group a mis en place une gouvernance ESG, av...” - STADA GroupObjectif de certification Ecovadis médaille d’or en 2026
“Neopharmed Gentili S.P.A vise l’obtention de la **...” - Neopharmed Gentili S.P.ARéduction des déchets et des émissions de CO2
“Takeda réduit ses déchets et ses émissions de CO2” - Takeda64% of similar organizations communicate on CSR issues
+568 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports